Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Quick facts

Marketed products

• Rifampicin Capsules · Infectious Disease
  Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.

Phase 3 pipeline

• Hydroxycarbamide Tablets · Oncology; Hematology
  Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis.
• Jaktinib · Other
• Placebo to match Hydroxycarbamide
  This is a placebo formulation designed to match the appearance and administration of hydroxycarbamide for use as a control in clinical trials.
• Placebo to match Jaktinib
  This is a placebo formulation designed to match the appearance and administration of Jaktinib, a JAK inhibitor, for use as a control in clinical trials.
• ZG006 · Oncology
  ZG006 is a monoclonal antibody targeting PD-1.

Phase 2 pipeline

• Jaktinib Hydrochloride Tablets
• ZG005

Phase 1 pipeline

• [14C]Donafenib
• [14C]-Jaktinib
• Alkotinib · Other
• Alkotinib（300mg)
• CM4307
• Donafenib Tosilate Tablets
• Gecacitinib Hydrochloride Tablets
• ZG19018
• ZG2001 Tosilate Tablets
• ZGGS15

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Suzhou Zelgen Biopharmaceuticals Co.,Ltd portfolio CI brief
• Suzhou Zelgen Biopharmaceuticals Co.,Ltd pipeline updates RSS